The Danish Biotech company failed to exit to Bristol-Myers Squibb in late 2017 but has now raised DKK 590m from existing and new investors. Novo Seeds is the largest stakeholder and the new investors are a.o. American-based Orbimed and Spanish-based venture fund Ysios Capital. Prior to the capital raise, Galecto had received DKK 75m in funding.
